Please assess the completion status of the following clinical trial:

Trial Title: Hypothalamic-Pituitary-Adrenal (HPA) Axis Study in Adult and Adolescent Subjects With Perennial Allergic Rhinitis (PAR)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Informed Consent~* Male or female subjects 12-45 years of age~* Documented history of perennial allergic rhinitis~* General good health~* Other criteria apply~Exclusion Criteria:~* History of physical findings of nasal pathology (within 60 days prior to Screening Visit 1)~* Participation in any investigational drug study 30 days preceding Screening Visit 1~* History of respiratory infection/disorder with 14 days preceding Screening Visit 1~* Use of any prohibited concomitant medications

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants self-administered 4 actuations (two per nostril) of placebo HFA once daily each morning for 6 weeks (42 days) as double-blind therapy for BDP. During week 6 (days 36-42), participants also took a placebo capsule as double-blind therapy for prednisone.
- BDP HFA 320 µg/day (Type: EXPERIMENTAL): Participants self-administered 4 actuations (two per nostril) of 80 µg BDP HFA once daily each morning for 6 weeks (42 days). During week 6 (days 36-42), participants also took a placebo capsule as double-blind therapy for prednisone.
- Prednisone (Type: ACTIVE_COMPARATOR): Participants self-administered 4 actuations (two per nostril) of placebo HFA once daily each morning for 6 weeks (42 days) as double-blind therapy for BDP. During week 6 (days 36-42), participants also took a 10/mg a day prednisone capsule.

Based on this trial design, predict the completion outcome and termination type (if applicable).